"FAS Russia has agreed on the first two pharmaceutical manufacturers the maximum selling price for the drug for the treatment of COVID-19 with the international non-proprietary name (INN) Favipiravir," the agency said in a statement, quoted by RIA Novosti.
It is noted that the decision to agree on a price of 100 rubles per tablet was made by all members of the Commission of the Ministry of Health of Russia on the formation of lists of drugs in the presence of representatives of pharmaceutical manufacturers.
According to the Federal Antimonopoly Service, the overall reduction in the maximum selling price for the drug was more than 50%.
It is noted that this will increase the availability of the drug for the population of Russia.
It is specified that after registration of the maximum selling price for the drug favipiravir, its maximum retail price in Moscow, taking into account surcharges, may be 6,875 rubles, including VAT, for a package of 50 tablets.
Earlier, the head of the Ministry of Industry and Trade Denis Manturov said that prices for drugs based on favipiravir for the treatment of patients with coronavirus had already more than halved in the country.